Guggenheim raised the firm’s price target on Pfizer (PFE) to $35 from $33 and keeps a Buy rating on the shares. Pfizer’s acquisition of Metsera (MTSR) is “a wise strategic move” to gain traction in the rapidly growing obesity market following recent setbacks with the company’s internal oral GLP-1 programs, the analyst tells investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Novo Nordisk Stock (NVO) Under Pressure as Rival Eli Lilly Joins the $1 Trillion Club
- Pfizer Completes $5 Billion Public Offering
- RFK told CDC to change website language on autism and vaccines, NYT reports
- Pfizer says FDA approves Padcev-Keytruda combo for certain patients
- Pfizer, Tris Pharma to pay Texas $41.5M to settle ADHD drug suit